An interventional study of 0.76% Sodium Monofluorophosphate Dentifrice and 0.454% Stannous Fluoride Dentifrice in Gingival Diseases, sponsored by Procter and Gamble. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-26.
Sponsored by Procter and Gamble · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Gingival Diseases with a site in United States — 8 open to participants now, 9 under way, none of them phase 3. Gingival Diseases · United States.
Among the 22 studies in Gingival Diseases with a site in United States, this one is the 3rd largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2022, is one of 12 with no phase, and was the 19th registered.
88 studies on the registry are indexed under Gingival Diseases; 23 are open to participants now.
Browse Gingival Diseases studies →8 of the 22 studies in Gingival Diseases with a site in United States are open now. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+ · Women only
Erchonia Corporation · Sites in United States
Ages 22–75
Massachusetts General Hospital · Sites in United States
Ages 18–75 · Healthy volunteers
University of Alabama at Birmingham · Sites in United States
Ages 18–85 · Healthy volunteers
National Institute of Dental and Craniofacial Research (NIDCR) · Sites in United States
Ages 7–100 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 15 Gingival Diseases studies recruiting now, 6 (40%) set no upper age limit and 5 (33%) stop at 75 or younger; 6 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2022.
This study's enrollment of 120 is above the median of 46 across 69 interventional studies indexed under Gingival Diseases.
Median enrollment 52 across the 20 interventional studies, 387 across the 2 observational. Of the 12 that completed or were terminated, 6 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 22 have an industry lead sponsor. The 10 most frequent:
Procter and Gamble is the lead sponsor of 83 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 10 (100%) have results posted.
Procter and Gamble has 1 study filed under Gingival Diseases — fewer than ten, so there is no comparison to draw.
3 of the studies in Gingival Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06185075University of MichiganInfluence of Implant Crown Transmucosal Contour Design on Soft and Hard Tissue Clinical Outcomes | 2026-12-01 |
| NCT06656325Erchonia CorporationAn Evaluation of the Effect of the Erchonia FX-405 Laser as an Adjunctive Treatment of Periodontitis | 2027-06-01 |
| NCT05384132University of Alabama at BirminghamNovel Dental Gel as an Adjunct to Scaling and Root Planing | 2027-10-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 22 studies in Gingival Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this learning clinical study is to evaluate the effects of formulation chemistry on gingivitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0.76% Sodium Monofluorophosphate
Drug: 0.76% Sodium Monofluorophosphate Dentifrice
0.454% Stannous Fluoride
Drug: 0.454% Stannous Fluoride Dentifrice
0.454% Stannous Fluoride, 4.7 pH
Drug: 0.454% Stannous Fluoride Dentifrice
0.454% Stannous Fluoride, 5.8 pH
Drug: 0.454% Stannous Fluoride Dentifrice
Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
Number Bleeding Sites
Number of bleeding sites derived from the Löe-Silness Gingivitis Evaluation based on a validated assessment of gingival health looking at inflammation and bleeding based on a 4 point range 0 (normal gingiva) to 3 (severe inflammation).
Time frame: 3 months, 1 month
Löe-Silness Gingivitis Evaluation
Löe-Silness Gingivitis Evaluation is a validated assessment of gingival health looking at inflammation and bleeding based on a 4 point range 0 (normal gingiva) to 3 (severe inflammation).
Time frame: 3 months, 1 month
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2022 to primary completion in Jun 2022, 2 months.
Of 43 interventional studies with no phase under Gingival Diseases, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 25. This study's 2 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tin Fluorides